BOTW
ALXN

Bank of the West’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of the West’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,657
Closed -$305K – 230
2021
Q2 		$305K Sell
1,657
-343
-17% -$58.9K 0.03% 197
2021
Q1 		$306K Sell
2,000
-43
-2% -$6.65K 0.03% 192
2020
Q4 		$319K Sell
2,043
-577
-22% -$74.1K 0.04% 186
2020
Q3 		$300K Sell
2,620
-650
-20% -$70.1K 0.04% 181
2020
Q2 		$367K Sell
3,270
-2,539
-44% -$270K 0.05% 190
2020
Q1 		$521K Sell
5,809
-17,989
-76% -$1.77M 0.08% 172
2019
Q4 		$2.57M Sell
23,798
-8,926
-27% -$955K 0.3% 88
2019
Q3 		$3.21M Sell
32,724
-2,117
-6% -$239K 0.39% 74
2019
Q2 		$4.56M Buy
34,841
+1,384
+4% +$178K 0.54% 51
2019
Q1 		$4.52M Buy
33,457
+304
+0.9% +$37.8K 0.53% 52
2018
Q4 		$3.23M Buy
33,153
+3,092
+10% +$365K 0.39% 76
2018
Q3 		$4.18M Sell
30,061
-7,984
-21% -$1M 0.49% 62
2018
Q2 		$4.72M Buy
38,045
+2,809
+8% +$328K 0.58% 50
2018
Q1 		$3.93M Sell
35,236
-2,238
-6% -$268K 0.49% 63
2017
Q4 		$4.48M Sell
37,474
-11,144
-23% -$1.36M 0.56% 60
2017
Q3 		$6.82M Sell
48,618
-526
-1% -$71.5K 0.86% 35
2017
Q2 		$5.98M Buy
49,144
+2,067
+4% +$241K 0.77% 38
2017
Q1 		$5.71M Buy
47,077
+3,909
+9% +$504K 0.72% 44
2016
Q4 		$5.28M Sell
43,168
-5,986
-12% -$732K 0.73% 43
2016
Q3 		$6.02M Buy
49,154
+5,710
+13% +$735K 0.83% 32
2016
Q2 		$5.07M Buy
43,444
+3,585
+9% +$509K 0.72% 38
2016
Q1 		$5.55M Buy
39,859
+3,256
+9% +$478K 0.77% 34
2015
Q4 		$6.98M Buy
36,603
+3,531
+11% +$617K 0.97% 26
2015
Q3 		$5.17M Buy
33,072
+861
+3% +$157K 0.82% 32
2015
Q2 		$5.82M Buy
32,211
+8,076
+33% +$1.39M 0.83% 37
2015
Q1 		$4.18M Buy
24,135
+1,058
+5% +$192K 0.59% 54
2014
Q4 		$4.27M Buy
23,077
+183
+0.8% +$33.9K 0.62% 54
2014
Q3 		$3.8M Buy
22,894
+704
+3% +$116K 0.64% 53
2014
Q2 		$3.47M Buy
22,190
+625
+3% +$98.7K 0.54% 70
2014
Q1 		$3.28M Sell
21,565
-1,191
-5% -$189K 0.54% 65
2013
Q4 		$3.02M Sell
22,756
-513
-2% -$61.6K 0.48% 70
2013
Q3 		$2.7M Sell
23,269
-1,613
-6% -$177K 0.49% 71
2013
Q2 		$2.29M Buy
+24,882
New +$2.4M 0.43% 80

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of the West's ALXN Position: Q3 2021 in Review

Bank of the West sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,657 shares — an estimated $305K sold.

Bank of the West first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $6.98M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of the West reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of the West sold 1,657 Alexion Pharmaceuticals shares in Q3 2021, an estimated $305K.
  • Bank of the West first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of the West's Alexion Pharmaceuticals position peaked at $6.98M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of the West's 13F filing for Q3 2021, filed 9 Nov 2021.